Alkaptonuria

Overview

Alkaptonuria (AKU) is an ultra-rare inherited metabolic disease caused by disease-causing variants in both copies of the HGD gene. The missing or poorly functioning homogentisate 1,2-dioxygenase enzyme allows homogentisic acid (HGA) to accumulate; HGA darkens urine and, over decades, forms pigment deposits known as ochronosis in cartilage and other connective tissues. Alkaptonuria—Past, Present and Future (pubmed.ncbi.nlm.nih.gov)

People with AKU often develop spinal and large-joint pain, early severe osteoarthritis, tendon problems, kidney or prostate stones, and heart-valve disease, usually becoming clinically prominent from adulthood onward. Damage that has already occurred is difficult to reverse, so present care combines monitoring and treatment of complications—including pain management and joint replacement when needed—with HGA-lowering treatment using nitisinone where available. Alkaptonuria—Past, Present and Future (pubmed.ncbi.nlm.nih.gov) In the European Union, nitisinone (Orfadin) is authorized for adults with AKU; it lowers HGA production but also raises blood tyrosine, requiring biochemical, dietary, and eye monitoring. Orfadin EPAR (ema.europa.eu)

Scope of Recent Research (2020–present)

Recent AKU research has been active but remains concentrated in a small international network. The dominant near-term question has been how effectively and safely nitisinone can suppress HGA and slow clinical progression; the main cure-oriented questions are whether liver-directed restoration of HGD can provide durable metabolic correction and whether some missense HGD variants can be rescued with small-molecule pharmacological chaperones. SONIA 2 trial (pubmed.ncbi.nlm.nih.gov) AAV liver-directed HGD therapy abstract (researchportal.vub.be) HGD chaperone screening assay (openalex.org) As of September 8, 2026, the cited evidence supports meaningful disease modification with nitisinone and preclinical progress toward gene replacement, but not a demonstrated curative therapy in people.

Major Breakthroughs and Emerging Therapies

Metabolic suppression with nitisinone. The pivotal recent clinical advance was the 2020 SONIA 2 trial, in which 10 mg daily nitisinone reduced 24-hour urinary HGA by 99.7% at 12 months versus no treatment and produced a significantly smaller rise in the composite AKU Severity Score Index over four years. SONIA 2 trial (pubmed.ncbi.nlm.nih.gov) This is not a molecular cure: nitisinone blocks an upstream enzyme, reducing formation of HGA rather than repairing the defective HGD gene or replacing HGD itself. Alkaptonuria—Past, Present and Future (pubmed.ncbi.nlm.nih.gov) Nevertheless, its ability to reduce HGA and partially reverse visible ochronotic pigmentation provides the strongest current evidence that longstanding biochemical injury can be modified. Ochronosis reversal with nitisinone (pubmed.ncbi.nlm.nih.gov)

Gene replacement. A 2023 conference report described liver-directed delivery of a functional human HGD sequence using an adeno-associated virus (AAV) vector in Hgd-deficient mice. The investigators described metabolic correction in the mouse model, a particularly relevant strategy because the liver is the main site in which HGD normally clears circulating HGA. AAV liver-directed HGD therapy abstract (researchportal.vub.be) This is the clearest recent potentially curative approach: instead of continually blocking HGA production, it aims to restore the missing enzymatic step. However, the reported work is a conference poster in mice, not a peer-reviewed human clinical study. AAV liver-directed HGD therapy abstract (researchportal.vub.be)

Variant-specific enzyme rescue. For people whose HGD protein is produced but unstable because of a missense variant, pharmacological chaperones are being explored. These small molecules would bind and stabilize the altered enzyme so it can fold and function better. A 2025 study reported a bacterial high-throughput screening system designed to identify such chaperones against human HGD missense variants. HGD chaperone screening assay (openalex.org) This approach could be oral and mutation-selective, but it would not be expected to help people whose variants yield no usable HGD protein.

Combination and tissue-protection approaches. Research groups are also testing antioxidants and anti-inflammatory strategies as add-ons to HGA lowering, seeking to reduce oxidative stress, inflammation, and downstream tissue injury rather than cure the genetic defect. The current Italian ApreciseKUre program specifically proposes evaluation of compounds such as N-acetylcysteine, ascorbic acid, and methotrexate in cell-based and data-driven precision-medicine studies. ApreciseKUre precision-medicine project (unibo.it) These are supportive experimental strategies, not established curative treatments.

Clinical Trials and Experimental Approaches

The major recently reported interventional trial is SONIA 2, a four-year, multicenter, randomized, open-label, evaluator-blinded phase III study run through the DevelopAKUre consortium at sites in the United Kingdom, France, and Slovakia. It randomized 138 adults with symptomatic AKU to nitisinone 10 mg daily or no treatment. SONIA 2 trial (pubmed.ncbi.nlm.nih.gov) The trial was supported through the European Commission’s FP7 DevelopAKUre program, coordinated by Royal Liverpool and Broadgreen University Hospitals NHS Trust, with Swedish Orphan Biovitrum as the industry partner supplying nitisinone and regulatory support. DevelopAKUre project fact sheet (cordis.europa.eu) Its outcomes led to the 2020 European authorization of Orfadin for adult AKU. EMA AKU treatment announcement (ema.europa.eu)

No human HGD gene-replacement, gene-editing, RNA, or cell-therapy trial is reported in the sources reviewed here. The principal cure-directed genetic result is therefore still the AAV-HGD mouse experiment. AAV liver-directed HGD therapy abstract (researchportal.vub.be) The U.S. National Institutes of Health continues to list a recruiting observational AKU study at the NIH Clinical Center in Bethesda, Maryland; it supports natural-history and clinical investigation rather than testing a curative intervention. NIH Alkaptonuria study (clinicaltrials.gov)

Methodologies and Scientific Approaches

AKU cure research uses liver-relevant genetic disease models, especially Hgd-deficient mice, to test whether restoring HGD activity lowers systemic HGA. The AAV program uses liver-directed viral gene delivery, while its outcome concept—metabolic correction—depends on measuring HGA and clinical-pathology consequences of HGA exposure. AAV liver-directed HGD therapy abstract (researchportal.vub.be) Human studies have used 24-hour urinary HGA, serum HGA, serum tyrosine, eye examinations, and the composite AKU Severity Score Index to connect biochemical control with disease progression. SONIA 2 trial (pubmed.ncbi.nlm.nih.gov)

Cell models are being used to study how HGA drives reactive oxygen species, inflammation, amyloid-like changes, and cartilage damage. A 2024 in-vitro model exposed human chondrocyte-like cells to HGA to investigate inflammatory and amyloidogenic processes, offering a platform for testing tissue-protective combinations before human studies. In-vitro inflammatory and amyloidogenic AKU model (pubmed.ncbi.nlm.nih.gov) ApreciseKUre integrates patient samples, metabolomics, proteomics, laboratory models, and artificial-intelligence-assisted clinical data tools to identify biomarkers, predict progression, and stratify patients for future trials. ApreciseKUre precision-medicine project (unibo.it)

Leading Institutions and Funding

The University of Liverpool and Liverpool University Hospitals have been central to AKU clinical development through the National Alkaptonuria Centre and the multinational SONIA program. SONIA 2 trial (pubmed.ncbi.nlm.nih.gov) DevelopAKUre brought together these UK leaders with centers in France, Slovakia, Italy, Sweden, patient advocates at the AKU Society, and industry partner Swedish Orphan Biovitrum. DevelopAKUre project fact sheet (cordis.europa.eu) The project had a total cost of approximately €11.2 million, including a European Commission contribution of €5,999,999. DevelopAKUre project fact sheet (cordis.europa.eu)

Vrije Universiteit Brussel has led the reported AAV-HGD mouse gene-therapy work with collaborators from Liverpool and other institutions. AAV liver-directed HGD therapy abstract (researchportal.vub.be) The University of Siena and University of Bologna are leading the more recent ApreciseKUre precision-medicine effort; the Bologna component lists €95,540 in institutional project support for a 24-month program running from November 2023 to February 2026. ApreciseKUre precision-medicine project (unibo.it)

Strengths, Limitations, and Challenges

The field’s major strength is that AKU has a direct, measurable metabolic driver: HGA. Nitisinone can reduce that driver dramatically, and SONIA 2 linked this biochemical effect to slower progression on a clinically meaningful composite score. SONIA 2 trial (pubmed.ncbi.nlm.nih.gov) Long-term observational analysis also suggests that the higher 10 mg dose may slow progression more than 2 mg, although higher-dose treatment was associated with more corneal keratopathy and requires careful tyrosine control. Nitisinone dose comparison (pubmed.ncbi.nlm.nih.gov)

The central limitation is that nitisinone requires ongoing treatment and does not repair HGD or reliably reverse established joint, spine, or valve damage. Alkaptonuria—Past, Present and Future (pubmed.ncbi.nlm.nih.gov) Gene replacement could, in principle, be a one-time etiologic treatment, but the AAV-HGD evidence remains preclinical; durability, adequate delivery to human liver cells, immune responses to vector or HGD, dose selection, and long-term safety must all be established. AAV liver-directed HGD therapy abstract (researchportal.vub.be) Access is also a challenge: an analysis of rare-disease medicine development noted that some treatment centers reported inability to prescribe nitisinone despite its European authorization, illustrating that regulatory approval does not automatically ensure affordable or equitable access. Rare-disease public–private partnerships (onlinelibrary.wiley.com)

Outlook and Future Directions

AKU is closer to effective disease modification than to a proven cure. The next milestones to watch are publication of full peer-reviewed AAV-HGD mouse data, reproducibility and long-term durability studies, toxicology and manufacturing work needed before a first-in-human gene-therapy trial, and discovery of chaperone compounds that restore activity in defined HGD missense variants. AAV liver-directed HGD therapy abstract (researchportal.vub.be) HGD chaperone screening assay (openalex.org) In parallel, earlier diagnosis, sustained HGA suppression, tyrosine management, and better biomarkers may preserve tissue while genuinely curative approaches mature. ApreciseKUre precision-medicine project (unibo.it)

References

• Alkaptonuria—Past, Present and Future — Ranganath et al., 2023.
• SONIA 2 trial — Ranganath et al., 2020.
• Orfadin EPAR — European Medicines Agency, 2025.
• Ochronosis reversal with nitisinone — Ranganath et al., 2020.
• AAV liver-directed HGD therapy abstract — Lequeue et al., 2023.
• HGD chaperone screening assay — Lequeue et al., 2025.
• ApreciseKUre precision-medicine project — University of Bologna, 2023.
• DevelopAKUre project fact sheet — European Commission CORDIS, 2021.
• EMA AKU treatment announcement — European Medicines Agency, 2020.
• NIH Alkaptonuria study — ClinicalTrials.gov, National Institutes of Health, accessed 2026.
• In-vitro inflammatory and amyloidogenic AKU model — Braconi et al., 2024.
• Nitisinone dose comparison — Ranganath et al., 2021.
• Rare-disease public–private partnerships — Rosenberg et al., 2023.